Advanced in Akesson Syndrome

Ewa Hainaut-Wierzbicka

CHU De Poitiers
Poitiers, FR 
Advanced in Akesson Syndrome
CHU De Poitiers
Poitiers, FR 
OverviewLocationsClinical Research

Overview

Ewa Hainaut-Wierzbicka practices in Poitiers, France. Ms. Hainaut-Wierzbicka is rated as an Advanced expert by MediFind in the treatment of Akesson Syndrome. Her top areas of expertise are Akesson Syndrome, Systemic Mastocytosis, Cutis Gyrata Syndrome, and Mast Cell Activation Syndrome (MCAS).

Her clinical research consists of co-authoring 28 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Akesson Syndrome.

Gender
Female

Locations

CHU de Poitiers
Poitiers, France
Other Locations
CHU Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Enrollment Status: Completed
Publish Date: May 15, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: Imiquimod Cream+Surgery, Surgery
Study Phase: Phase 3
View 1 Less Clinical Trial

28 Total Publications

Heparanase 1 produced by keratinocytes contributes to psoriatic inflammation by promoting neutrophil infiltration.
Heparanase 1 produced by keratinocytes contributes to psoriatic inflammation by promoting neutrophil infiltration.
Journal: International immunopharmacology
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hainaut-Wierzbicka's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile